PARP inhibitors are a group of pharmacological inhibitors of the enzyme polymerase ADP ribosome (PARP).They are developed for multiple indications.PARP inhibitors can enhance the efficacy of radiotherapy, alkalization agents and platinum-based chemotherapy by inhibiting DNA damage repair and promoting apoptosis of tumor cells. Parp (Poly Adp-Ribose Polymerase) inhibitors is very effective in treating solid tumors and other diseases.Such as advanced ovarian cancer, fallopian tube cancer and primary peritoneal cancer.

Market Analysis and Insights: Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market
The global PARP (Poly ADP-ribose Polymerase) Inhibitors market size is projected to reach US$ 21490 million by 2027, from US$ 2861 million in 2020, at a CAGR of 32.8% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global PARP (Poly ADP-ribose Polymerase) Inhibitors market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global PARP (Poly ADP-ribose Polymerase) Inhibitors market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global PARP (Poly ADP-ribose Polymerase) Inhibitors market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global PARP (Poly ADP-ribose Polymerase) Inhibitors market.

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Scope and Market Size
PARP (Poly ADP-ribose Polymerase) Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global PARP (Poly ADP-ribose Polymerase) Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Olaparib
Talazoparib

Segment by Application
Ovarian Cancer
Breast Cancer
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie
Pfizer
AstraZeneca
GlaxoSmithKline
Clovis Oncology
Everest Pharmaceuticals